Good - you've researched, used the power of AI and the study's rationale is laudable.

For what it's worth, I like DECIPHER and was a bit disappointed when my Mayo radiation oncologist asserted she didn't think it was necessary for me and my Gleason 4+3=7 . I didn't challenge her on this because I had already come to the conclusion that near castrate level total testosterone (mine was 50 ng/dL) was likely advantageous. I had nine of 13 cores in my biopsy as being positive which made me extra reluctant to pass on androgen deprivation even before meeting with the radiation oncologist.

I also get how you have some degree of anxiety about enrolling in the clinical study. For what it's worth, I also decided to enroll in a clinical study for the treatment of my situation. Of course my study was different from yours. In particular, my study involved an experimental treatment arm that:
(1) narrowed the margin of he radiated prostate from the standard four millimeters to only a two millimeter margin,
(2) reduced the number of SBRT radiation sessions from five to two and
(3) used a new, MRI custom redesigned radiation field for each of the two treatment sessions.

Part of the reason I said "yes" to this study was because I had heard some encouraging similar "less radiation" comments from a New York University Langone study that I believe was started in 2024. As it turns out, however, I was randomized to the control group in the study and received the standard of care, normally applicable five SBRT session treatment.

Hey - I'll be cheering for favorable results in your study. Best wishes!

Would you mind sharing the name and NCT number of your clinical trial?

My clinical trial was the "Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer" The trial number was NCT06325046. It was started in 2024 and I was the 51st person randomized to the trial which seeks approximately 150 participants.